Navigation Links
Charting the Biosimilar and Biobetter Development Pipeline (2013)

London (PRWEB) October 22, 2013

If you need to understand the important biosimilar and biobetter drug developments worldwide then this report is critical.

The promise of biosimilars has been great but beyond the first wave of products progress has been slow. With a number of high-value biologics, particularly monoclonal antibodies such as Herceptin, Avastin, Remicade and Humira, losing patent expiry in the coming years the potential for biosimilars remains high. With greater clarity on regulatory approval and the demand of health payers for low cost medicines, the drive to develop a viable biosimilar market will continue to grow.

Who are the companies involved? What does their portfolio look like? What stage are they at? Which products offer the best potential in terms of competitor development? Critical questions needing robust answers. That is where Charting the Biosimilar and Biobetter Development Pipeline (2013) comes in.

Scope of the Report

Charting the Biosimilar and Biobetter Development Pipeline (2013) will help you to:

•Understand the landscape of biosimilar/biobetter development through pipeline analysis of all known biosimilar developers worldwide
•Drill down to discover the levels of potential biosimilar and biobetter competition by therapy area, drug class, development status, and country
•Establish the level of biosimilar/biobetter competition to leading brands
•Learn which biosimilar developers are potential future competitors or collaborators
•Interrogate the development portfolio of over 300 companies and discover which are the leaders in biosimilar/biobetter development
•Identify development hotspots and know where research is taking place



The massively expanded second edition of this leading drug intelligence report provides a complete, practical and highly-detailed insight into the status of 868 biosimilar/biobetter drugs in development from over 300 companies worldwide. Widely considered to be the most comprehensive analysis of its type, Charting the Biosimilar and Biobetter Development Pipeline (2013) is delivered in two modules:

1. Biosimilar Datafile – New this edition!
Enjoy the practical benefits of a Microsoft Excel file containing data on biosimilar and biobetter drugs currently marketed or known to be in clinical development worldwide. Each drug can be seen in the context of data on their biologic reference products and content can readily be filtered on key indicators such as:

•Product Name/Development Code
•HQ Location
•Reference Product
•Originator Company
•Product Type
•Stage of Development (US)
•Stage of Development (EU)
•Therapy Area
•EU Patent Expiry
•US Patent Expiry
•Brand Name (reference products)
•Sales Value (reference products)

Using the tables provided you can effortlessly drill down into the content to identify biosimilars/biobetters in development by country, company, ATC classification, stage of development therapeutic area. Better still, the data can easily be exported to your own analytics or competitive intelligence system.

2. Biosimilar Development Analysis Report
This completely updated and expanded report volume utilises the Datafile content to produce more than 200 clear tables, charts, graphs and maps to provide “at a glance” insights into high-level trends and significant developments. Areas covered include:

•Leading biosimilar companies - number of biosimilar products in portfolio
•Geographic distribution of biosimilar/biobetter research
•Biosimilar development pipelines by 14 compound class and therapy areas
•Biosimilar development pipelines by therapy area
•Biobetter developments by compound class and therapy area
•Biobetters in development by 13 therapy areas

Who should read this report?

Product managers at pharma/biotech companies with original biologics:
Identify how many biosimilars versions of your products are being developed and by whom

Product managers at biosimilar developers:
Know how many biosimilars are being developed in different therapy areas or of different originator products so that you can identify opportunity gaps/areas with less competition

Heads of licensing at pharma/biotech companies: Use the database to identify biosimilars developers that may want to license in/out their products – whilst also assessing the competitive environment for any products that they may currently license.
Investment managers at venture capital firms, seed funding bodies and investment banks:
Assess the investment potential of companies and their development pipelines: the risks are high but potential reward is great for those that bring product to market.


•Executive Summary & Introduction
•Definitions and methodology
•Reference products
•Biosimilars in development
oBy earliest potential launch date – US & EU
oBy class and earliest potential launch date in the US & EU (total number)
oDevelopers countries and regions in development by drug class
oBy drug class
•Leading biosimilar companies - number of biosimilar products in portfolio
•Biosimilar development pipelines by 14 compound class and therapy areas including
oAntithrombotic Agents
oBlood Coagulation Factors
oSomatropin and Somatropin Agonists
oParathyroid Hormones and Analogues
oAntineoplastic Monoclonal Antibodies
oMuscle Relaxants and Other Musculoskeletal Drugs
•Biosimilar development pipelines by therapy area
outoimmune disease
oCardiovascular disease
oEndocrine and metabolic disorders
oInfectious and parasitic diseases
oMusculoskeletal disorders
oNeuromuscular diseases
•Biobetter developments by compound class and therapy area
oBiobetter development by therapy area and stage of development
oBiobetters in development by ATC class
•Biobetters in development by 13 therapy areas including
oAutoimmune diseases
oEndocrine and metabolic disorders
oInfectious and parasitic diseases
oMusculoskeletal disorders and neuromuscular diseases
oRespiratory disease
oWound care

Read the full report:

Charting the Biosimilar and Biobetter Development Pipeline (2013)

For more information:
Sarah Smith
Research Advisor at
Tel: +44 208 816 85 48

Read the full story at

Source: PRWeb
Copyright©2012 Vocus, Inc.
All rights reserved

Related biology technology :

1. Electronic Health Records: Charting the Future of Health Care - 2013 Report
2. Biosimilars Need Same Names as Original Biologics, Hospira Says at World Health Organization (WHO) Meeting
3. Generics/Biosimilars Collection - Report Bundle
4. Physician Familiarity With Biosimilars Has Increased Significantly Over The Past Year
5. Surveyed U.S. Payers Are Significantly More Likely To Reimburse Biosimilars Developed By Multinational Manufacturers Compared With Those Developed By Regional Emerging Market Players
6. Nonclinical and Clinical Safety Assessment of Biosimilars, New Webinar Hosted by Xtalks
7. Monoclonal Antibodies Market in Rheumatoid Arthritis to 2018 - Market Characterized by Large and Diversified Pipeline and Low Threat of Biosimilar Sales Erosion
8. Pacific Biomarkers and Clinigene International To Announce Laboratory Solutions for Developers of Biosimilars at 2013 AAPS/ National Biotechnology Conference
9. Competitor Analysis: Therapeutic Proteins - Biosimilars, Biobetters & Biosuperiors
10. Challenges and Solutions in Conducting Biosimilar Trials, New Life Science Webinar Hosted by Xtalks
11. CHI Vice President Provides Testimony On Patient, Physician Notification of Biosimilar Substitution
Post Your Comments:
(Date:11/25/2015)... ... November 25, 2015 , ... ... were featured on AngelList early in their initial angel funding process. Now, they ... for individuals looking to make early stage investments in the microbiome space. ...
(Date:11/24/2015)... Therapeutics, Inc. (NASDAQ: HALO ) will be presenting at the ... on Wednesday, December 2 at 9:30 a.m. ET/6:30 a.m. PT . ... a corporate overview. th Annual Oppenheimer Healthcare Conference ... a.m. PT . Jim Mazzola , vice president of ... --> th Annual Oppenheimer Healthcare Conference in ...
(Date:11/24/2015)... , Nov. 24, 2015 /PRNewswire/ - Aeterna Zentaris Inc. ... IIROC on behalf of the Toronto Stock Exchange, confirms ... there are no corporate developments that would cause the ... --> --> About Aeterna Zentaris ... . --> Aeterna Zentaris is a specialty ...
(Date:11/24/2015)... ... November 24, 2015 , ... The Academy of Model Aeronautics (AMA), led by ... known as Multirotor Grand Prix, to represent the First–Person View (FPV) racing community. , ... have embraced this type of racing and several new model aviation pilots have joined ...
Breaking Biology Technology:
(Date:11/18/2015)... -- As new scientific discoveries deepen our understanding of how ... face challenges in better using that knowledge to guide ... more children continue to survive pediatric cancer, that counseling ... John M. Maris, M.D ., a pediatric ... . --> John M. Maris, M.D ...
(Date:11/17/2015)... PARIS , November 17, 2015 ... November 2015.   --> Paris from ... --> DERMALOG, the biometrics innovation leader, has invented the ... and fingerprints on the same scanning surface. Until now two ... fingerprints. Now one scanner can capture both on the same ...
(Date:11/17/2015)... LIVERMORE, Calif. , Nov. 17, 2015  Vigilant ... has joined its Board of Directors. ... Vigilant,s Board after recently retiring from the partnership at ... owning 107 companies with over $140 Billion in revenue.  ... performance improvement across all the TPG companies, from 1997 ...
Breaking Biology News(10 mins):